skip to Main Content

Welcome
to ACT

A specialised trials delivery organisation dedicated to blood cancers, working hand-in-hand with the UK haematology community to accelerate the delivery of commercial and investigator initiated trials.

Commercially competitive with the CRO sector, ACT funds and has direct access to the established TAP and IMPACT trials networks as well as immediate access to globally recognised haemato-oncology key opinion leaders across the UK.

Early engagement with us is proven to help with clinical development plans, study design and regulatory hurdles. All surplus income is utilised to support projects that benefit patients.

Prof. Charles Craddock
Founder

UK Blood Cancer Clinical Trials Customised to your needs

Direct Access to over 27 Research Centres across the UK embedded within the NHS

ACT funds the established and globally significant UK trials networks TAP and IMPACT.

Both networks have a strong track record of accelerated recruitment to practice informing drug, transplant and cell therapy trials. Gaining immediate access to our networks saves considerable time and resources, both in the set-up and management of your clinical trial and enables ongoing access to expert advice.

Prof. Chris Fox
Medical Director

Dr Pramila Krishnamurthy
Deputy Medical Director

Prof. Steven Knapper
Deputy Medical Director

Prof. Ronjon Chakraverty
Medical Director

Dr Wendy Ingram
Deputy Medical Director

Dr Victoria Potter
Deputy Medical Director

Our services

Haemato-oncology and UK Healthcare experts specialising in blood cancer trials ranging from new drug and combination studies to stem cell transplant and cellular therapy trials. Through expert knowledge and medical expertise as apply our know-how to the most complex studies to deliver transformative outcomes for the haemato-oncology community through the following:

We deliver a full suite of services depending on the need, from comprehensive clinical trial management to specific bespoke operational requirements

Reinvestment in the UK haemato-oncology trials infrastructure for further patient benefit

An emphasis on speed and efficiency

Direct, single point of access to leading research centres, opinion leading investigators and research nurses with a track record of efficient trial delivery

A diverse catchment population of around 20 million

Embedded world-class genomics, diagnostics and other translational science to generate practice changing data and support regulatory submissions

Support for regulatory and HTA submissions

Investigator initiated and industry-sponsored trials

  • Signal seeking
  • Registrational quality data
  • Identify novel therapeutic indications
  • Support for reimbursement and patient access

Testimonials